Immunocine
A Breakthrough in Rebuilding Immune Response to Cancer

Cancer doesn’t always sneak past the human body’s defense mechanisms. Sometimes, the immune system simply fails to recognize the threat. This immunological ignorance lets tumors grow unchecked. Immunocine has developed a breakthrough immunotherapy platform that restores the immune system’s ability to recognize and fight cancer.

After years of research, the advanced immunology company identified a critical flaw in the communication loop. Dendritic cells, the immune system’s key sentinels, often fail to deliver two essential signals—one to recognize an abnormality, and another to declare it dangerous.

“The immune system’s ignorance isn’t passive, it’s a fixable mistake,” says Matthew Halpert, founder and CEO. “Once we correct it, the body sees and fights.”

With a proprietary Double-Loaded dendritic cell technology, Immunocine delivers both signals in the correct biological context. The therapy restores immune surveillance and initiates a precise, natural attack on cancer.

The therapy does not broadly stimulate the immune system. Instead, it educates the system, showing it exactly what to target and why. Delivered in a non-toxic, outpatient setting, it complements existing treatment regimens while preserving future options.

While outcomes vary based on tumor type, treatment history and the patient’s immune resilience, restoring recognition gives the immune system a fighting chance it previously lacked. For many patients, it represents the first meaningful opportunity to activate a true immune response guided by the body’s biology.

Reprogramming Immune Precision for Long-Term Defense

The process begins with a precision-engineered, lab-guided approach. Critical precursor cells are collected from the patient’s blood to be differentiated into dendritic cells, along with a personalized tumor sample usually obtained by biopsy. The cells are then exposed to the tumor’s comprehensive mRNA (a.k.a. “genetic blueprint”) and entire protein signature (a.k.a. “expression profile”) in the lab, providing a complete biological profile beyond isolated markers and mutations, and not necessarily dependent on what the underlying mutation specifically was.

This simultaneous dendritic cell education is the critical signal itself, recalibrating the entire immune system to finally recognize this signature as a threat. Now, a focused and effective physiological response can truly take place, rather than continued ignorance of the tumor as benign.

The activated dendritic cells are reintroduced near functional, draining lymph nodes relevant to the tumors, where they recruit T cells, alert other immune players and trigger a targeted, systemic attack. This immune recalibration establishes enduring surveillance against recurrence in a non-toxic, controlled manner, avoiding inflammation overload, gene editing and other high-risk interventions. It provides a clean reset rooted in the body’s natural immune pathways.

“We’re not a cancer company that offers immune-based therapy,” says Halpert. “We’re an immunology company using advanced technology to help cancer patients.”

Immunotherapy Made Safe and Transparent

Immunocine reimagines immunotherapy as outpatient, biology-first care, free from the complexity of traditional, pharma-reliant models. From cell collection to reinfusion, the process avoids cryogenic storage, genetic modification and synthetic carriers.

Because the therapy does not compromise immune function through toxicity, it can possibly be offered earlier in the treatment journey, before chemotherapy or radiation suppresses the immune system. It flips the conventional sequence, enabling immune activation when it can be most effective, not as a last-ditch effort. However, when and where this strategy is best implemented is truly a case-by-case decision, and Immunocine is always clear with the patient about what they believe the optimal strategy to be for legitimate and long-term success.

Another key differentiator is transparent, upfront pricing. Unlike many other clinics that employ questionable billing practices or surprise patients with unexpected charges throughout treatment, Immunocine offers a comprehensive treatment program for a single, clearly stated fee with no hidden costs or premium add-ons. All clinically relevant techniques, which can differ some from patient to patient based on the case, are included in the program rather than being marketed as separate services. While personalized, hig-hintegrity cancer treatment will always represent a significant investment in the non-insurance space, Immunocine is committed to delivering exceptional value and ensuring patients understand exactly what they're receiving for their investment.

“We don’t sell treatments,” says Halpert. “We just deliver what’s right for the patient.”

Immunocine primes the immune system to recognize tumors, often causing cancers to express PD-L1 as they fight back against immune attack. This creates an opportunity for checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 to become effective, even in previously unresponsive cases. While Immunocine doesn't include checkpoint inhibitors in its core treatment, many PD-L1–negative tumors convert to PD-L1–positive within four to six months post-therapy. This allows for selective, short-course checkpoint therapy when immune activation warrants it, maximizing impact while minimizing side effects—rather than defaulting to indefinite treatment.

Stored Today, Life-Saving Tomorrow

Immunocine has also developed The Preserve, a tissue-banking program that proactively secures future immunotherapy options for patients whose treatment choices might otherwise be limited. Because effective immune training requires both viable tumor tissue and healthy dendritic cells, The Preserve allows patients, particularly those at high risk or undergoing preventive surgery, to store a portion of their tumor. The window to train the immune system may close once a tumor is removed and discarded or degraded, making early collection critical.

The process is simple. Patients receive a kit ahead of surgery, enabling the surgical team to collect and ship tumor material for cryostorage. For under $5,000, half of which is credited toward future treatment if used, The Preserve secures a vital option should cancer return or if the patient wishes to engage their immune system and improve their overall odds of success.

“Too often, we meet patients we could help, but they have no usable tumor material left,” says Halpert. “Our initiative changes that.” Previous tissue stored for pathological scoring is rarely usable.

The forward-looking solution is designed for high-risk patients within their standard of care course or those undergoing preventive surgery. But maybe more than a service, The Preserve reflects a shift in care strategy. It brings immunotherapy into the conversation earlier, allowing patients to shape their path proactively. Preparedness matters only if treatment is within reach, which is why Immunocine keeps its therapy accessible.

From Stage 4 to Thriving

The most compelling part of Immunocine’s work goes beyond theory. It’s reflected in the stories of people whose lives have been transformed. The outcomes are real, documented and, in many cases, life-changing. Patients with advanced-stage cancers—bladder, breast, pancreatic and prostate, to name a few—have seen tumors shrink, vanish or stabilize well past clinical expectations.

Brian’s story exemplifies how Immunocine changes the odds. Diagnosed with Stage 4 bladder cancer and having exhausted conventional treatment options, he arrived at Immunocine. His case was complex, but the team wasn’t deterred. They turned to the platform’s core strength in training the immune system to recognize a patient’s unique tumor. Within months, Brian’s scans were clear. Even his oncologists called it “unbelievable.” Today, he’s thriving.

These are not miracle cases. They are biological proofs of concept and evidence that when the immune system sees the target clearly, it can act with strength and sustained impact.

Equally important is the way patients describe their experience. Reviews consistently highlight the honest and compassionate approach, grounded in transparency. Immunocine doesn’t accept patients it cannot help. It communicates candidly if the immune system is too compromised or the cancer is fast-moving. The resulting ethical clarity builds trust and fosters hope without illusion.

Immunocine avoids hype, celebrity endorsements or aggressive marketing. The company’s growth has been organic, driven by results, referrals and a commitment to science. With treatment centers in Cancun and a soon-to-open in Cabo San Lucas in Mexico and a preserve center in Scottsdale, Arizona, it is scaling across borders.

Immunocine reframes immunotherapy as a biologically intelligent, patient-led strategy, grounded in immune logic and scientific foresight that opens the door to interventions that work because the biology finally sees what’s at stake.